High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma
Marie‐Hélène Delfau‐Larue(Inserm), Eva Hoster(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Catherine Thiéblemont(Université Paris Cité), Martin Dreyling(LMU Klinikum), Josette Brière(Assistance Publique – Hôpitaux de Paris), Olivier Casasnovas, Olivier Hermine(Centre National de la Recherche Scientifique), Elizabeth Macintyre(Inserm), Fabrice Jardin(Laboratoire National Henri Becquerel), Gilles Salles(Memorial Sloan Kettering Cancer Center), Françoise Berger(Hôpital Lyon Sud), Wolfgang Hiddemann(Christian-Albrechts-Universität zu Kiel), Pierre Feugier(Centre Hospitalier Régional et Universitaire de Nancy), Michael Unterhalt, Corinne Haïoun(Assistance Publique – Hôpitaux de Paris), Christiane Pott(University Hospital Schleswig-Holstein), Vincent Ribrag(Institut Gustave Roussy)
Cited by 157
Related Papers
<i>LMO2</i> -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
|Science|2003|3.5k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
|Journal of Clinical Investigation|2008|1.8k